Back to top
more

Viking Therapeutics (VKTX)

(Real Time Quote from BATS)

$75.59 USD

75.59
1,532,959

-0.84 (-1.10%)

Updated May 2, 2024 03:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Intercept (ICPT) to Restructure Operations, Cut Workforce

by Zacks Equity Research

Intercept (ICPT) looks to restructure operations, discontinue all NASH-related investments and reduce its workforce by one-third.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XBI

Here's Why Hepion Pharma (HEPA) is Up More Than 80% in Two Days

by Zacks Equity Research

Hepion Pharmaceuticals' (HEPA) lead pipeline candidate, rencofilstat, demonstrates improvements in physiologic liver function and key NASH biomarkers in the phase II ALTITUDE-NASH study in advanced NASH patients.

Intercept (ICPT) NASH Treatment Fails to Get GIDAC Recommendation

by Zacks Equity Research

Intercept's (ICPT) NASH treatment does not succeed in getting GIDAC's recommendation for an approval. The committee recommends deferring approval until clinical data from another study is available.

Intercept (ICPT) Down Ahead of GIDAC Meeting for NASH Treatment

by Zacks Equity Research

Intercept (ICPT) falls 14.7% a couple of days before the scheduled GIDAC meeting to review its NASH treatment on concerns of adverse events.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Viking (VKTX) Up 12% as VKTX-2809 Meets Goals in NASH Study

by Zacks Equity Research

A mid-stage study data shows that Viking Therapeutics' (VKTX) VK2809 achieved reductions in liver fat content in patients with biopsy-confirmed NASH, following 12-weeks of treatment.

Ligand (LGND) Up 3% on Raised '23 View, Beats on Q1 Earnings

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) announces better-than-expected results in first-quarter 2023. Management raises 2023 financial outlook.

Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

Intercept (ICPT) reports wider-than-expected loss in the first quarter of 2023. Revenues rise year over year.

Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback

by Zacks Equity Research

Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.

Viking (VKTX) Announces Clinical Data for Metabolic Disorders

by Zacks Equity Research

Viking (VKTX) announces positive clinical data, evaluating VK2735 to treat metabolic disorders. It is also initiating an early-stage extension study on the same.

Intercept (ICPT) Stock Down on FDA Committee Update on NDA

by Zacks Equity Research

Intercept (ICPT) declines on news of a GIDAC meeting to discuss the NDA for the OCA for NASH in May.

Heres Why Intercept (ICPT) Stock is Up 28.7% in 3 Months

by Zacks Equity Research

Intercept (ICPT) gains 28.7% in the past 3 months on NDA's acceptance for NASH treatment and Ocaliva's performance.

Intercept (ICPT) Q4 Earnings Beat, Ocaliva Sales Increase

by Zacks Equity Research

Intercept (ICPT) posts a narrower loss in Q4 due to higher revenues.

Chemomab (CMMB) Mid-Stage Study for NASH Meets Primary Goal

by Zacks Equity Research

Chemomab's (CMMB) phase II study evaluating CM-101 in NASH patients met its primary endpoint of safety and tolerability.

Madrigal (MDGL) Soars as Resmetirom Meets Goal in NASH Study

by Zacks Equity Research

Madrigal's (MDGL) phase III MAESTRO-NASH study evaluating resmetirom for treating nonalcoholic steatohepatitis and liver fibrosis meets both primary endpoints. Stock rises.

Viking Therapeutics, Inc. (VKTX) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Viking Therapeutics, Inc. (VKTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Intercept (ICPT) Q3 Earnings Miss, Sales Beat, View Raised

by Zacks Equity Research

Intercept (ICPT) posts a wider loss in Q3 due to a loss on extinguishment of debt but beats on sales. Management increases annual sales guidance.

Intercept (ICPT) Stock Gains 13% in 3 Months: Here's Why

by Zacks Equity Research

Intercept (ICPT) gains 13% in the past three months on positive regulatory and pipeline updates.

Akero Therapeutics (AKRO) Up on Positive Data from NASH Study

by Zacks Equity Research

Akero Therapeutics (AKRO) reports positive top-line data from a mid-stage study evaluating its lead candidate, efruxifermin (EFX), in patients with NASH, fibrosis stage 2 or 3 (F2-F3). Stock up.

    Intercept (ICPT) Earnings Miss, Sales Top Estimates in Q2 (Revised)

    by Zacks Equity Research

    Intercept (ICPT) posts a wider Q2 loss while sales beat estimates. The company reissues guidance.

    Intercept (ICPT) Earnings and Sales Miss Estimates in Q2

    by Zacks Equity Research

    Intercept (ICPT) posts a wider Q2 loss and sales miss estimates. The company reissues guidance.

    Intercept (ICPT) Announces Delay in Meeting With the FDA

    by Zacks Equity Research

    Intercept (ICPT) faces yet another setback as its resubmission for NDA for OCA for NASH gets delayed.

    Pfizer (PFE) Gets Fast Track Designation for NASH Therapy

    by Zacks Equity Research

    Pfizer (PFE) obtains Fast Track designation for its investigational combination therapy - ervogastat and clesacostat for the treatment of NASH.